Bay­er con­tin­ues its cell and gene ther­a­py push, en­velop­ing dif­fer­ent projects un­der one strate­gic roof while hunt­ing new deals

Rough­ly five weeks af­ter buy­ing out Askle­pios — al­so known as AskBio — for up to $4 bil­lion, Bay­er is ham­mer­ing home its fo­cus on cell and gene ther­a­pies.

The Big Phar­ma an­nounced Wednes­day that it is es­tab­lish­ing a cell and gene ther­a­py plat­form with­in its phar­ma­ceu­ti­cals di­vi­sion in or­der to con­sol­i­date all of its re­lat­ed projects un­der one um­brel­la. Re­searchers will con­tin­ue work­ing and de­vel­op­ing ex­per­i­men­tal drugs on their own, Bay­er said, while the ex­ecs will lay out and de­fine the over­all strat­e­gy and look to swing some more deals.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER